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The purpose of the study was to determine the prevalence in liver transplant (OLTx) 
patients of the hepatitis markers (anti-A, anti-B, anti-C, anti-D and HB,Ag) and the 
interrelationships between markers and patients' sexes, ages, dates of transplant, clini-
copathological diagnoses, and short-term survivals. Slightly more than half of the pa-
tients were male. Anti-A and anti-B were about evenly distributed between male and 
female. Anti-C, anti-D, and HB,Ag were far more common in males. Age and year of 
transplant showed only a moderate increase in anti-A with increasing age. Anti-A was 
found ill 57% of all patients, anti-B in 18%, anti-C in 17%, and HB,Ag in 17%. Anti-D was 
tested only in patients who were positive for anti-B or HB,Ag and occurred in 21 (1/%) of 
185. The poorest short-term survival occurred in males who showed both anti-A and 
HB,Ag. 
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LiYer disease of sufficient severity to necessitate 
liver transplant may arise from a variety of irrevers-
ible diseases, including acute or chronic infection 
with one or more of the hepatitis viruses. In an 
attempt to assess the role of these viruses, we have 
determined their prevalence in baseline plasma 
specimens from 573 patients undergoing primary 
orthotopic liver transplant (OLTx). These plasma 
samples were residual from coagulation studies, 
and their use was approved by the University of 
Pittsburgh Institutional Review Board. Because the 
hepatitis C testing was done before the test systems 
were approved by the Food and Drug Administra-
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tion (FDA), the results were treated as experimen-
tal and not reported to patients' physicians. 
Plasma samples had been stored at - 70° C for up 
to eight years (1982-1989). No patient had received 
FK705 before the blood was tested. Antibodies to 
hepatitis A, B, and C and the antigen, HBsAg, were 
assayed in all samples. Anti-D (delta) was assayed 
only in those positive for HBsAg and/or anti HBsAg 
(anti-B). 
The primary aim of the study was to determine 
the prevalence of these markers. A relationship 
between positive markers or marker patterns was 
sought with sex, age, year of transplant, clinico-
pathological diagnosis, and short-term survival. 
MATERIALS AND METHODS 
Plasma Samples. These were "left over" from plasma 
taken for coagulation studies on either the baseline or first 
operative (preliver excision) sample and stored frozen at 
-700 C for one to eight years. Because the samples were 
left over, the project was approved by the University of 
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TABLE I. PATIENT SEX-RELATIONSHIP TO SHORT-TERM SURVIVAL AND HEPATITIS MARKERS* 
Markers! 
Sex Survit·aO· None Anti-A Anti-B Anri-C Anti-D eB~g 
F 267 (47) 226 (85) 78 (29) 153 (57) 53 (20) 29 (11) 3 (I) 26 (10) 
M 306 (53) 244 (80) 80 (26) 176 (58) 51 (17) 71 (23) 18 (6) 70 (23) 
---
573 470 (82) 158 (28) 329 (57) 104 (18) 100 (17) 21 (4) 96 (17) 
p= 0.157 NS NS NS <0.0002 0.005 <0.0001 
*Values are numbers; percentages are in parentheses. 
tLiving at discharge from hospital admission, which includes primary liver transplant. 
:j:Percentages do not add up to 100 because one patient may have multiple markers. 
Pittsburgh's IRB as exempt from the need for patient 
consent. When this research was started, the test for 
hepatitis C virus (HCY) was not yet approved by the 
FDA and all studies were nonlinked, ie, patient samples 
were coded and results were not reported to the patient or 
their physicians. 
Samples were chosen randomly from those that ap-
peared to have sufficient volume. The original plan was to 
choose about 600, roughly half of those available. The 
panel of diagnoses (see Tables 4 and 6) is not necessarily 
representative of that of all patients coming to OL Tx over 
these years. 
Clinicopathological Diagnoses. The diagnosis was made 
by clinical history, available serological tests, and exam-
ination of the extirpated native liver (1). Standard histo-
pathological criteria were applied to the tissue sections 
(2). 
Hepatitis markers. The following tests were carried out 
on each of 573 samples in Central Blood Bank's labora-
tories: anti-A-The RIA systems from Abbott Laborato-
ries (Havab- and Havab-M-RIA); anti-B-the EIA sys-
tem from Abbott Laboratories (Ausab EIA); anti-C-the 
EIA system from Chiron, distributed by Ortho Diagnos-
tics (hepatitis C virus encoded antigen (recombinant 
C100-3) Ortho HCY ELISA test system); HBsAg-the 
EIA system from Abbott Laboratories (Auszyme-
Monoconal). Anti-delta or anti-D was tested only in the 
185 samples that were positive for HBsAg or for anti-B. 
The RIA system from Abbott Laboratories (Antidelta) 
was used. 
Marker Patterns. To express the various combinations 
of antibodies and antigen found, patterns were con-
structed in which each antibody is expressed by its letter 
if reactive, by a dot (.) if nonreactive, or by a slash (I) if 
not tested. Antibodies are positioned in order-ABCD. 
These are followed by a hyphen (-) and then the mark for 
the antigen: B if HB,Ag is positive and dot if negative. 
Statistical Methods. Statistical correlations and their 
significance were determined by the chi square test andlor 
Fisher's exact test. 
RESULTS 
Sex. Table 1 shows that there were 267 females 
(47%) and 306 males (53%) in this group of 573 
primary liver transplant patients. Short-term sur-
vival is slightly better with females (P = 0.157). No 
markers were found in 29% of females and 26% of 
males. Anti-A and anti-B were about evenly distrib-
uted between the sexes. On the other hand, anti-C, 
anti-D and HBsAg showed a striking difference, 
each being far less prevalent among females (all, P 
< 0.0002). 
Year of Birth. Table 2 divides the patients by year 
of birth. Here significant trends are not readily 
detectable. Patients' ages do not relate to short-
term survival or to the prevalence of markers with 
the exception of anti-A, which is more common in 
patients born before 1943 (P < 0.001). 
Year of OLTx. Table 3 divides the patients by 
year of primary liver transplant. No significant 
trends are apparent. 
TABLE 2. YEAR OF BIRTH-RELATIONSHIP TO SHORT-TERM SURVIVAL, HEPATITIS MARKERS, AND SEX· 
Markers * Sex 
Birth year N Sarviva/* None Anti-A t Anti-B Anti-C Anti-D eB~g F M 
08-22 19 19 (100) 3 (16) 15 (79) 6 (32) 4 (21) 1(5) 3 (16) 10 (53) 9 (47) 
23-32 120 91 (76) 29 (24) 77 (64) 22 (18) 14 (12) 2 (2) 21 (18) 49 (41) 71 (59) 
33-42 160 137 (86) 37 (23) 100 (63) 21 (13) 33 (21) 4 (3) 25 (18) 81 (51) 79 (49) 
43-52 163 133 (82) 57 (35) 80 (49) 30 (18) 30 (18) 8 (5) 29 (18) 67 (41) 96 (59) 
53-62 71 55 (77) 21 (30) 34 (48) 17 (24) 13 (18) 4 (6) 13 (18) 37 (52) 34 (48) 
63-71 40 35 (88) II (28) 23 (58) 8 (20) 6 (15) 2 (5) 5 (13) 23 (58) 17 (43) 
Total 573 470 (82) 158 (28) 329 (57) 104 (18) 100 (17) 21 (4) 96 (17) 267 (47) 306 (53) 
'See Table I. 
tDividing birth year into two groups: 08-42 and 43-71, anti-A is significantly greater in the older group, P = 0.0008. 
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TABLE 3. YEAR OF LIVER TRANSPLANT-RELATIONSHIP TO SHORT-TERM SURVIVAL, HEPATITIS MARKERS, AND SEX* 
Markers' Sex 
OLTx 
year N Survival* None Anti-A Anti-B Anti-C Anti-D HB,Ag F M 
1982 5 3 (60) 0(0) 3 (60) I (20) 2 (40) I (20) 3 (60) 2 (40) 3 (60) 7 (44) 9 (56) 
1983 16 \3 (82) 4 (25) 10 (63) 2 (13) 0(0) I (6) 3 (19) 20 (67) 10 (33) 1984 30 23 (77) 13 (43) 13 (43) 5 (17) 2(7) 3 (10) 7 (23) 19 (35) 
1985 54 43 (80) 14 (26) 34 (63) 7 (13) 6(11) 3 (6) 13 (24) 35 (65) 33 (48) 
1986 69 60 (87) 23 (33) 37 (54) 11(16) 13 (19) 2 (3) 10 (14) 36 (52) 63 (49) 1987 129 \04 (81) 31 (24) 80 (62) 18 (14) 22 (17) 4 (3) 19 (15) 66 (51) 119 (63) 1988 190 157 (83) 46 (24) 113 (59) 39 (21) 39 (21) 5 (3) 31 (16) 71 (37) 50 (62) 1989 80 67 (84) 27 (34) 39 (49) 21 (26) 14 (18) 2 (3) 10 (13) 30 (38) 
Total 573 470 (82) 158 (28) 329 (57) 104 (18) 100 (17) 21 (4) 96 (17) 267 (47) 306 (53) 
*See Table I. 
Clinicopathological Diagnosis. Table 4 shows that 
short-term survival for the entire group was 82%. In 
Budd-Chiari, Wilson's disease, and hepatitis B, it 
was 60%,67%, and 73%, respectively. Patients with 
no markers were most common in PSC (P < 
0.0001), PBC (P = 0.006), and malignancy (P = 
0.001). Anti-A was found in 57% of all patients. It 
was least frequent in PSC (P = 0.0001). Anti-B was 
found in 18% of all patients and varied from 10% in 
PBC to 32% in acute hepatitis. Anti-C was most 
frequent in NANB hepatitis (49%) but was also 
found in hepatitis B (35%) and cryptogenic cirrhosis 
(21%). HBsAg was found in 96 patients (17%), the 
large majority of which were diagnosed as having 
chronic hepatitis B, Budd-Chiari, Wilson's disease, 
or acute hepatitis. 
Table 4 also shows the sex distribution among the 
various diagnoses. Those suffering from PBC and 
from Budd-Chiari were 90% female. Hepatitis B 
(89%) and alcoholic cirrhosis (80%) occurred pri-
marily in males. Sclerosing cholangitis, malignancy, 
aI-antitrypsin deficiency, acute hepatitis, and cryp-
togenic cirrhosis all were found in 58% or more of 
males. 
Interrelationship Between Anti-B, Anti-D, and 
HBsAg and Short-Term Survival of Patients. HBsAg 
and anti-B were tested on all patient samples (573), 
but anti-D was done only when either or both of 
these were positive (I85 samples). Table 5 shows 
the results: 388 (68%) were negative for HBsAg and 
anti-B. HBsAg was positive in 96; alone in 66, with 
anti-D in 15, with anti-B in 10, and with both in 5. 
Anti-B was positive in 104; alone in 88, with anti-D 
in 1, and as stated in the last sentence, with HBsAg 
in 10 and with both in 5. Short-term survival is 
shown in the last column. Anti-B tended to have a 
beneficial effect, short-term survival being 90% (P 
= 0.08 vs other patients). Patients with HBsAg, 
TABLE 4. CLINICOPATHOLOGICAL DIAGNOSES-RELATIONSHIP TO SHORT-TERM SURVIVAL, HEPATITIS MARKERS, AND SEX' 
Markers* Sex 
Diaf(nosis/ 
Diseaset N Survival* None Anti-A Anti-B Anti-C Anti-D HB,Ag F M 
CC 100 85 (85) 20 (20) 61 (61) 24 (24) 21 (21) 0(0) 0(0) 42 (42) 58 (58) 
PBC 99 85 (85) 41 (41) 50 (50) 9 (9) 4 (4) o (0) 8 (8) 90 (90) 9 (10) 
PSC 81 66 (81) 40 (49) 30 (37) 14 (7) 6 (7) o (0) 2 (2) 30 (37) 51 (61) 
ALC 56 46 (82) 15 (27) 36 (64) 13 (13) 7 (13) 3 (5) 8 (14) II (20) 45 (80) 
HepB 55 40 (73) 0(0) 41 (75) 8 (35) 19 (35) 14 (25) 47 (85) 6(11) 49 (89) 
MA 54 46 (85) 24 (44) 25 (46) 9(11) 6(11) I (2) 7 (13) 22 (41) 32 (59) 
NANB 51 43 (84) 10 (20) 35 (69) 10 (49) 25 (49) 1 (2) 4 (8) 25 (49) 26 (51) 
AcH 31 26 (84) 1 (3) 23 (74) 10 (19) 6 (19) 2 (6) 10 (32) 13 (42) 18 (58) 
<XIAT 17 14 (82) 2 (12) 11 (59) 3 (18) 3 (I8) 0(0) 3 (18) 7 (41) 10 (59) 
Be 10 6 (60) 1 (10) 6 (60) I (10) I (10) 0(0) 4 (40) 9 (90) I (10) 
WD 9 6 (67) 0(0) 7 (78) 1(11) 2 (22) 0(0) 3 (33) 6 (66) 3 (33) 
Misc+ 10 7 (70) 4 (40) 4 (40) 2 (20) 0(0) 0(0) 0(0) 6 (60) 4 (40) 
Total 573 470 (82) 158 (28) 329 (57) 104 (18) 100 (17) 21 (4) 96 (17) 267 (47) 306 (53) 
'See Table I. 
tCC = cryptogenic cirrhosis; PBC = primary biliary cirrhosis, PSC = primary sclerosing cholangitis, ALC = alcoholic cirrhosis; HepB 
= hepatitis B, MA = malignancy; NANB = Non-A. non-B hepatitis; AcH = acute hepatitis; <XIAT = <XI-antitrypsin deficiency; BC 
= Budd-Chiari; WD = Wilson's disease. 
:j:Misc: uncertain diagnosis (8), posthepatic pediatric (I), hemachromatosis (I). 
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TABLE 5. NUMBERS AND SHORT-TERM SURVIVAL OF PATIENTS ABCD-. were not exemplified). The short-term sur-WITH HBsAG AND/OR ANTI-8 AND/OR ANTI-D 
vival appears to relate to the marker pattern. In the 
Survivalt lowest group in the left-hand column containing 
HB,A!? Anti-B* Anti-D Number No. % both anti-A and B antigen, the short-term survival is 
0 0 / 
significantly lower (72%) than in the other three 
388 318 82 groups combined (P < 0.02), including B antigen 0 + 0 88 79 90 
0 + + 1 0 0 without anti-A (86%) and anti-A without B antigen 
+ 0 0 66 48 73 (83%). 
+ 0 + 15 12 80 Marker patterns that occurred in more than 20 + + 0 10 10 100 
+ + 5 3 60 patients are as follows: A . .I-.(180), .. .1-.(58), AB .. -
Total: 573 470 82 .(45), A ... -B(34), .. CI.(27), A.CI-.(23), .. CI-.(23) 
+/0 +/0 21 15 71 and .B .. -.(22). Of these common patterns, reduced 
"With anti-B alone (P = 0.57) or in combination (P = 0.08) short-term survival was found only in A ... -B. 
survival was improved. 
tSee Table 1. 
DISCUSSION 
alone or in combination with anti-D, had short-term The testing of hepatovirus markers is important 
survivals of 71-73%. in OL Tx patients in two ways-in establishing a 
Hepatitis Marker Patterns. Table 6 shows, in the diagnosis and in demonstrating a risk factor. The 
left-hand column, the 24 patterns that were found high prevalence of anti-HAY (anti-A) in these pa-
(28 patterns are possible; .B.D-., .BC.-B, AB.D-., tients raises the questions of whether this virus has 
TABLE 6. MARKER PATTERNS-RELATIONSHIP TO SHORT-TERM SURVIVAL AND CLINICOPATHOLOGICAL DIAGNOSES 
Living 
Marker N N % CC PBC PSC ALC Hep8 MA NANB AeH a1AT BC WD Mise 
... 1-. 158 129 82 20 41 40 15 0 24 10 I 2 I 0 4 
.B .. -. 22 21 95 6 3 7 0 I 3 0 I 0 0 0 1 
.. C/-. 27 23 85 11 I 4 I 1 0 3 I 3 0 I I 
.BC.-. 7 7 100 2 0 0 1 1 0 3 0 0 0 0 0 
.BCD-. I 0 0 0 0 0 I 0 0 0 0 0 0 0 0 
215 180 84 39 45 51 18 3 27 16 3 5 1 1 6 
.... -B 19 16 84 0 4 0 0 6 I 0 3 I 3 1 0 
... D-8 I 1 100 0 0 0 0 1 0 0 0 0 0 0 0 
.B .. -8 4 4 100 0 0 0 I 0 1 0 2 0 0 0 0 
.B.D-B 1 1 100 0 0 0 1 0 0 0 0 0 0 0 0 
.. C.-B I I 100 0 0 0 0 1 0 0 0 0 0 0 0 
.. CD-8 2 I 50 0 0 0 0 2 0 0 0 0 0 0 0 
.BCD-B 1 1 100 0 0 0 0 1 0 0 0 0 0 0 0 
29 25 86 0 4 0 2 11 2 0 5 I 3 I 0 
A.'/-. 180 147 82 38 40 20 22 2 14 14 11 7 4 4 3 
AB .. -. 4S 40 89 15 5 7 7 1 0 2 4 2 1 0 1 
A.c/-. 23 19 83 7 1 1 1 0 3 10 1 0 0 0 0 
ABC.-. 14 II 79 1 0 0 I 1 3 S 2 0 0 1 0 
262 217 83 61 46 28 31 4 20 31 18 9 5 5 4 
A ... -B 34 24 71 0 2 1 4 19 3 0 2 1 0 2 0 
A .. D-B 4 3 75 0 0 0 0 4 0 0 0 0 0 0 0 
AB .. -B 5 5 100 0 I 0 0 2 I 0 0 I 0 0 0 
AB.D-B 2 I 50 0 0 () () 0 1 0 1 0 0 0 0 
A.C.-B 12 7 58 0 I I I 5 0 3 0 0 I 0 0 
A.CD-B 8 7 88 0 0 0 0 6 0 I I 0 0 0 0 
ABC.-B I I 100 0 0 0 0 0 0 0 I 0 0 0 0 
ABCD-B I 0 0 0 () 0 () 1 () () 0 () 0 0 0 
67 48 72 0 4 2 5 37 5 4 5 2 1 2 0 
Total 573 470 82 100 99 81 S6 55 54 51 31 17 10 9 10 
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been underestimated as a cause of clinical disease 
or as a synergist for other hepatoviruses or as a 
predisposing factor for subsequent nonviral dis-
eases. In other words, does a mild, limited hepatitis 
A infection leave enough liver damage to set the 
stage for additional liver disease? Only sclerosing 
cholangitis (PSC) shows no increase above the es-
timated US incidence rate of 35-40% in adults (3). 
Of particular interest is the recent description by 
Prochazka et al (4) of a strong genetic disposition in 
PSC. These authors demonstrated the HLA type 
DRW 52a in 100% of PSC patients tested. In this 
disease environmental factors such as virus expo-
sure may not play any significant role. Of the pa-
tients with anti-A, only two were positive for IgM 
and both had been diagnosed with acute hepatitis A. 
The hepatitis C virus (HCV) has been shown to 
be the major cause of NANB hepatitis (5). In our 
series, 25 (49%) of the 51 patients diagnosed as 
having NANB hepatitis showed the anti-C marker 
alone or in combination. Of the entire group of 
OLTx patients anti-C was found in 17%, a value 
similar to the 21% found in Italy (6). 
The hepatitis D virus (delta agent) is an incom-
plete RN A virus that cannot enter mammalian cells 
without a hepatitis B DNA virus surface antigen 
coat (7). In this study anti-D was found in 20 of the 
96 positive for HBsAg (21 %) and also in one patient 
with anti-B and no measurable HBsAg in the circu-
lation. This may have been a patient just converting 
from antigen positive to antibody positive. 
Short-term survival used in many of these calcu-
lations is important only as it relates to periopera-
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tive deaths, rapid rejections, etc. Recurrence of 
disease, reinfection, rejection, etc, may not be ev-
ident at the time of hospital discharge, However, 
the best short-term prognosis for OLTx fits a female 
of any age with anti-B marker and the clinical diag-
nosis of primary biliary cirrhosis, cryptogenic cir-
rhosis, or malignancy. 
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